BACKGROUND: Pancreatic cancer ranks as the fourth leading cause of cancer death in the United States with 5-year survival ranging from 1% to 5%. Positron emission tomography (PET) is a metabolic imaging system that is widely used for the initial staging of cancer and detecting residual disease after treatment. There are limited data, however, on the use of this molecular imaging technique to assess early tumor response after treatment in pancreatic cancer. METHODS: The objective of the study was to explore the relationship of early treatment response using the F-fluorodeoxyglucose (FDG) PET with surgical outcome and overall survival in patients with locally advanced pancreatic cancer. FDG-PET measurements of maximum standardized uptake value and kinetic parameters were compared with the clinical outcome. RESULTS: Twenty patients were enrolled in the study evaluating neoadjuvant induction chemotherapy followed by concurrent chemoradiotherapy (chemo-RT) for locally advanced pancreatic cancer. All 20 patients had prestudy PET scans and a total of fifty PET scans were performed. Among patients who were PET responders (> or =50% decrease in standardized uptake value after cycle 1), 100% (2/2) had complete surgical resection. Only 6% (1/16) had surgical resection in the PET nonresponders (<50% decrease). Two patients did not have the second PET scan because of clinical progression or treatment toxicity. Mean survival was 23.2 months for PET responders and 11.3 months for nonresponders (P = 0.234). Similar differences in survival were also noted when response was measured using Patlak analysis. CONCLUSIONS: FDG-PET can aid in monitoring the clinical outcome of patients with locally advanced pancreatic cancer treated with neoadjuvant chemo-RT. FDG-PET may be used to aid patients who could have complete surgical resection as well as prognosticate patients' survival.
BACKGROUND:Pancreatic cancer ranks as the fourth leading cause of cancer death in the United States with 5-year survival ranging from 1% to 5%. Positron emission tomography (PET) is a metabolic imaging system that is widely used for the initial staging of cancer and detecting residual disease after treatment. There are limited data, however, on the use of this molecular imaging technique to assess early tumor response after treatment in pancreatic cancer. METHODS: The objective of the study was to explore the relationship of early treatment response using the F-fluorodeoxyglucose (FDG) PET with surgical outcome and overall survival in patients with locally advanced pancreatic cancer. FDG-PET measurements of maximum standardized uptake value and kinetic parameters were compared with the clinical outcome. RESULTS: Twenty patients were enrolled in the study evaluating neoadjuvant induction chemotherapy followed by concurrent chemoradiotherapy (chemo-RT) for locally advanced pancreatic cancer. All 20 patients had prestudy PET scans and a total of fifty PET scans were performed. Among patients who were PET responders (> or =50% decrease in standardized uptake value after cycle 1), 100% (2/2) had complete surgical resection. Only 6% (1/16) had surgical resection in the PET nonresponders (<50% decrease). Two patients did not have the second PET scan because of clinical progression or treatment toxicity. Mean survival was 23.2 months for PET responders and 11.3 months for nonresponders (P = 0.234). Similar differences in survival were also noted when response was measured using Patlak analysis. CONCLUSIONS:FDG-PET can aid in monitoring the clinical outcome of patients with locally advanced pancreatic cancer treated with neoadjuvant chemo-RT. FDG-PET may be used to aid patients who could have complete surgical resection as well as prognosticate patients' survival.
Authors: Corneline J Hoekstra; Sigrid G Stroobants; Egbert F Smit; Johan Vansteenkiste; Harm van Tinteren; Pieter E Postmus; Richard P Golding; Bonne Biesma; Frans J H M Schramel; Nico van Zandwijk; Adriaan A Lammertsma; Otto S Hoekstra Journal: J Clin Oncol Date: 2005-11-20 Impact factor: 44.544
Authors: Stephen G Swisher; Jeremy Erasmus; Mary Maish; Arlene M Correa; Homer Macapinlac; Jaffer A Ajani; James D Cox; Ritsuko R Komaki; David Hong; Hoon K Lee; Joe B Putnam; David C Rice; W Roy Smythe; Linh Thai; Ara A Vaporciyan; Garrett L Walsh; Tsung-Teh Wu; Jack A Roth Journal: Cancer Date: 2004-10-15 Impact factor: 6.860
Authors: R S Yeung; J L Weese; J P Hoffman; L J Solin; A R Paul; P F Engstrom; S Litwin; M J Kowalyshyn; B L Eisenberg Journal: Cancer Date: 1993-10-01 Impact factor: 6.860
Authors: Naveen M Kulkarni; Lorenzo Mannelli; Marc Zins; Priya R Bhosale; Hina Arif-Tiwari; Olga R Brook; Elizabeth M Hecht; Fay Kastrinos; Zhen Jane Wang; Erik V Soloff; Parag P Tolat; Guillermo Sangster; Jason Fleming; Eric P Tamm; Avinash R Kambadakone Journal: Abdom Radiol (NY) Date: 2020-03
Authors: Avani S Dholakia; Muhammad Chaudhry; Jeffrey P Leal; Daniel T Chang; Siva P Raman; Amy Hacker-Prietz; Zheng Su; Jonathan Pai; Katharine E Oteiza; Mary E Griffith; Richard L Wahl; Erik Tryggestad; Timothy Pawlik; Daniel A Laheru; Christopher L Wolfgang; Albert C Koong; Joseph M Herman Journal: Int J Radiat Oncol Biol Phys Date: 2014-04-18 Impact factor: 7.038
Authors: Avani S Dholakia; Amy Hacker-Prietz; Aaron T Wild; Siva P Raman; Laura D Wood; Peng Huang; Daniel A Laheru; Lei Zheng; Ana De Jesus-Acosta; Dung T Le; Richard Schulick; Barish Edil; Susannah Ellsworth; Timothy M Pawlik; Christine A Iacobuzio-Donahue; Ralph H Hruban; John L Cameron; Elliot K Fishman; Christopher L Wolfgang; Joseph M Herman Journal: J Radiat Oncol Date: 2013-09-22
Authors: Julie Leca; Sébastien Martinez; Sophie Lac; Jérémy Nigri; Véronique Secq; Marion Rubis; Christian Bressy; Arnauld Sergé; Marie-Noelle Lavaut; Nelson Dusetti; Céline Loncle; Julie Roques; Daniel Pietrasz; Corinne Bousquet; Stéphane Garcia; Samuel Granjeaud; Mehdi Ouaissi; Jean Baptiste Bachet; Christine Brun; Juan L Iovanna; Pascale Zimmermann; Sophie Vasseur; Richard Tomasini Journal: J Clin Invest Date: 2016-10-04 Impact factor: 14.808
Authors: Willemieke S Tummers; Juergen K Willmann; Bert A Bonsing; Alexander L Vahrmeijer; Sanjiv S Gambhir; Rutger-Jan Swijnenburg Journal: Pancreas Date: 2018-07 Impact factor: 3.327